At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,010 enrolled
Drug / intervention
Cetuximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
In Brief
A Phase 3 clinical trial evaluating Cetuximab and Panitumumab for Metastatic Colorectal Cancer. Completed, enrolled 1,010 participants across 152 sites in 29 countries.
Detailed Summary
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesAustralia, Belgium, Bulgaria, Canada, China, Czechia, France, Hong Kong, India, Israel, Italy, Latvia, Lithuania, Malaysia, Netherlands, Peru, Philippines, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartFeb 2010
Primary CompletionFeb 2013
Study CompletionMar 2017
TodayJul 2026
First PostedOct 26, 2009
Enrollment StartFeb 2, 2010
Primary CompletionFeb 5, 2013
Study CompletionMar 7, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 16.7 years ago
Interventions
Cetuximabdrug
Administered by intravenous infusion
Panitumumabdrug
Administered by intravenous infusion